 Benzylidene Compounds
"Benzylidene Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds containing the PhCH= radical.
| Descriptor ID |
D001597
|
| MeSH Number(s) |
D02.455.426.559.389.150
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzylidene Compounds".
Below are MeSH descriptors whose meaning is more specific than "Benzylidene Compounds".
This graph shows the total number of publications written about "Benzylidene Compounds" by people in this website by year, and whether "Benzylidene Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2008 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 1 | 2 | | 2012 | 0 | 1 | 1 | | 2013 | 1 | 0 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Benzylidene Compounds" by people in Profiles.
-
Lewis AS, Olincy A, Buchanan RW, Kem WR, Picciotto MR, Freedman R. Effects of a nicotinic agonist on the Brief Psychiatric Rating Scale five-factor subscale model in schizophrenia. Schizophr Res. 2018 05; 195:568-569.
-
Kem WR, Olincy A, Johnson L, Harris J, Wagner BD, Buchanan RW, Christians U, Freedman R. Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation. Neuropsychopharmacology. 2018 02; 43(3):583-589.
-
Wylie KP, Smucny J, Legget KT, Tregellas JR. Targeting Functional Biomarkers in Schizophrenia with Neuroimaging. Curr Pharm Des. 2016; 22(14):2117-23.
-
Fu RH, Wang YC, Liu SP, Shih TR, Lin HL, Chen YM, Tsai RT, Tsai CH, Shyu WC, Lin SZ. Dryocrassin suppresses immunostimulatory function of dendritic cells and prolongs skin allograft survival. Cell Transplant. 2014; 23(4-5):641-56.
-
Freedman R. a7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. Annu Rev Med. 2014; 65:245-61.
-
Zhang S, Cheng K, Wang X, Yin H. Selection, synthesis, and anti-inflammatory evaluation of the arylidene malonate derivatives as TLR4 signaling inhibitors. Bioorg Med Chem. 2012 Oct 15; 20(20):6073-9.
-
Olincy A, Freedman R. Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the a7 nicotinic receptor. Handb Exp Pharmacol. 2012; (213):211-32.
-
Tregellas JR, Tanabe J, Rojas DC, Shatti S, Olincy A, Johnson L, Martin LF, Soti F, Kem WR, Leonard S, Freedman R. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry. 2011 Jan 01; 69(1):7-11.
-
Stevens KE, Cornejo B, Adams CE, Zheng L, Yonchek J, Hoffman KL, Christians U, Kem WR. Continuous administration of a selective alpha7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice. Brain Res. 2010 Sep 17; 1352:140-6.
-
Loram LC, Harrison JA, Chao L, Taylor FR, Reddy A, Travis CL, Giffard R, Al-Abed Y, Tracey K, Maier SF, Watkins LR. Intrathecal injection of an alpha seven nicotinic acetylcholine receptor agonist attenuates gp120-induced mechanical allodynia and spinal pro-inflammatory cytokine profiles in rats. Brain Behav Immun. 2010 Aug; 24(6):959-67.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|